About us
Ramesh Jayaraman has thirty years of experience in drug discovery and development in Cancer, Infection, and Metabolic disorders.
His expertise is in ADME, pharmacokinetics, pharmacodynamics, pharmacokinetics/pharmacodynamics [PK/PD]), modelling and simulation, preclinical development (IND enabling), and clinical PK. He has published 23 articles on preclinical and clinical ADME, PK, PK/PD in cancer and infection drug discovery and development.
In cancer he worked in preclinical and clinical development projects at S*BIO (Singapore) that delivered targeted anti-cancer molecules (SB1518, Pacritinib [VONJO, approved for treatment of Myelofibrosis], Pracinostat (SB939) , SB1317, and SB1578) to the clinic.
In AstraZeneca R& D, India, he worked in anti-tuberculosis drug discovery, in ADME, PK and PK/PD, in lead identification and lead optimization programs. He characterized the PK/PD of anti-tuberculosis drugs that helped to set the basis for developing a progression cascade for LI-LO programs. He was trained and mentored by Prof. Johan Gabrielsson in PK/PD (AZ, Molndal, Sweden).
He was a co-founder and Director of TheraIndx Lifesciences, a preclinical R&D services company, where he served as the chief scientific officer. As a CSO he oversaw projects in pharmacokinetics, pharmacology, PK/PD, exploratory toxicology, established preclinical PK/PD models such as the neutropenic thigh and lung infection models in rat and the cUTI model in mice.
He is an editorial board member for the journal “Current Drug Metabolism”.
Vision
To provide consultancy services to Pharmaceutical and Biotechnology companies and Academic Institutions in drug discovery and development.
Mission
To provide quality consultancy services in pharmacokinetics (PK), pharmacodynamics (PD), pharmacokinetics/pharmacodynamics (PK/PD), ADME, pharmacology, preclinical development, and clinical development.